WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, October 9, 2018

Gel-Injection Laryngoplasty Overcomes Hypophonia in Parkinson's Disease

Daniel M. Keller, PhD     October 06, 2018







HONG KONG — Vocal cord augmentation by injection laryngoplasty produced both objective and subjective improvements of voice for patients with Parkinson's disease (PD).
Although otolaryngologists have safely injected collagen or gels into the vocal folds for many years to treat atrophy from many causes, the technique has not been widely used in PD. Olga Klepitskaya, MD, University of Colorado Anschutz Medical Campus, Aurora, told Medscape Medical News, "As a neurologist, we don't know about that."
"Our data demonstrated improvement in voice quality due to glottis closure in PD after vocal fold injection augmentation," the researchers conclude. "Further studies of the effect of short- and long-acting vocal fold augmentation are warranted."
Their findings were presented here at the International Congress of Parkinson’s Disease and Movement Disorders 2018.
Speech and voice impairments affect up to 90% of patients with PD, with hypophonia being the major voice disorder and vocal fold atrophy being a major cause. Vocal fold atrophy from disuse, as well as from normal aging, causes glottic insufficiency, resulting in the vocal folds failing to fully approximate; air escapes during vocalization, projection is decreased, and the voice is softer and quieter.
But one day, Klepitskaya said, a patient in her clinic told her that an otolaryngologist "injected something" in his throat, "and I speak better."
So in collaboration with otolaryngologist Matthew Clary, MD, she performed a retrospective and prospective observational study of vocal fold augmentation with carboxymethylcellulose (CMC) gel injection, using objective and subjective measures of the effect on voice and speech among patients with clinically significant voice impairment and glottic insufficiency secondary to idiopathic PD.
Patients (n = 29) received CMC gel injections, expected to last up to 3 months, under direct laryngoscopic visualization. A main objective outcome was the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V), performed on deidentified audio recordings by three independent speech therapists blinded to the state of treatment.
Other objective measures were the glottic closure time and supraglottic constrictions. Recordings were made at screening, 1 month later (baseline), and 1 and 5 months after injection.
Patients had a mean age of 72.9 ± 5.87 years with a mean PD duration of 13.0 ± 10.59 years, 25 of the 29 were male, and 27 had had their 1-month follow-up visit by the time of data analysis.
On CAPE-V measures, there were statistically significant improvements in overall severity, breathiness, and loudness 1 month after injection.
"The only thing that got worse is called roughness, but that would be expected because of the better volume," Klepitskaya said. Twenty-four of the 27 subjects (89%) reported a positive effect of treatment 1 month after injection.
Table 1. CAPE-V Scores (Mean ± SD) 
End PointScreening VisitBaseline1-Month Post InjectionP Value: 1-Month vs ScreeningP Value: 1-Month vs Baseline
Overall Severity57.6 ± 20.658.5 ± 20.345.0 ± 19.6.0443.0012
Roughness22.3± 13.122.9 ± 14.631.3 ± 17.8.0355.2887
Breathiness36.0 ± 26.930.4 ± 25.119.5 ± 24.0.041.0279
Strain32.2 ± 23.731.3 ± 26.926.8 ± 17.3.6588.1424
Loudness52.7 ± 22.853.5 ± 26.434.3 ± 29.7.0048.001
Glottic closure time increased (improved) 16.43% 1 month after injection compared with the screening visit, and it increased by 10.82% compared with baseline (< .001 for both). There was no significant difference at baseline compared with the screening visit 1 month earlier.
There were no differences pre- and postinjection for the subjective outcomes of the Voice Handicap Index-10 (VHI-10), a 10-question tool measuring patients' perception of their voice, and the Eating Assessment Tool (EAT-10) for their perception of their swallowing and eating abilities.
f the CMC gel was successful, by 3 months the effect would wear off. Then the otolaryngologist would inject a calcium hydroxyapatite paste, which Klepitskaya said should last up to 18 months, so she is following the patients to see when that effect will wear off.
She said she "absolutely" advocates using the short-acting gel first to see if the voice improves, and then going to the long-acting one if warranted. In this trial, a large majority of the patients benefited from the initial short-acting gel injection.
Joseph Quinn, MD, Oregon Health and Science University, Portland, said he was impressed with the data. "I think it could really make a difference for our patients," he said. "I like the fact that there's an objective appearance that makes the diagnosis and then a short-term trial period. I think all those are really attractive."
He noted that sometimes physicians do not appreciate some of the changes that patients have that are not specific to PD, such as those that just accompany normal aging, such as voice changes. Those, too, can affect functioning and quality of life, he said.
The study was partially funded by the Davis Phinney Foundation. Klepitskaya had no relevant disclosures. Quinn reported receiving search support from abbvie and Sanofi.
International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2018: Abstract 220. Presented October 6, 2018.
https://www.medscape.com/viewarticle/903076#vp_1

No comments:

Post a Comment